Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread.

ABSTRACT:

Background

Metastatic disease is the main cause of breast cancer (BC)-related deaths, but prediction of metastases remains challenging especially in the large and diverse group with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors. Molecular tumor features beyond currently used markers could provide important information for stratifying metastatic risk. To allow for the discovery of new subtypes and molecular tumor features associated with metastatic spread, i.e., both lymph node and distant metastases, we here leverage advances in proteomic profiling of tumors.

Methods

We developed a protocol for proteome and phosphoproteome analysis using label-free data independent acquisition (DIA) liquid chromatography tandem mass spectrom

SUBMITTER: Mosquim Junior S 

PROVIDER: S-EPMC12810005 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature